Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
Akari Therapeutics announced the acceptance of an Australian patent covering its proprietary second-generation Thailanstatin analog payload used in antibody-drug conjugates (ADCs) targeting cancer. This approval broadens the company's global intellectual property protection for its PH1 RNA splicing modulator payload platform, supporting the advance…